These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 3931992

  • 1. Amikacin + ceftazidime therapy of experimental right-sided Pseudomonas aeruginosa endocarditis in rabbits.
    Bayer AS, Lam K, Norman D, Kim KS, Morrison JO.
    Chemotherapy; 1985; 31(5):351-61. PubMed ID: 3931992
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. In vivo efficacy of azlocillin and amikacin versus ciprofloxacin with and without amikacin in experimental right-sided endocarditis due to Pseudomonas aeruginosa.
    Bayer AS, Kim KS.
    Chemotherapy; 1986; 32(4):364-73. PubMed ID: 2942342
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of ceftazidime and aztreonam alone or in combination with amikacin in experimental left-sided Pseudomonas aeruginosa endocarditis.
    Pefanis A, Giamarellou H, Karayiannakos P, Donta I.
    Antimicrob Agents Chemother; 1993 Feb; 37(2):308-13. PubMed ID: 8452362
    [Abstract] [Full Text] [Related]

  • 6. Therapy of experimental Pseudomonas endocarditis with high-dose amikacin and ticarcillin.
    Choi C, Bayer AS, Fujita NK, Lam K, Guze LB, Yoshikawa TT.
    Chemotherapy; 1983 Feb; 29(4):303-12. PubMed ID: 6872621
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
    Robaux MA, Dube L, Caillon J, Bugnon D, Kergueris MF, Navas D, Le Conte P, Baron D, Potel G.
    J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
    [Abstract] [Full Text] [Related]

  • 9. Pseudomonas peritonitis in neutropenic rats treated with amikacin, ceftazidime and ticarcillin, alone and in combination.
    Shyu WC, Nightingale CH, Quintiliani R.
    J Antimicrob Chemother; 1987 Jun; 19(6):807-14. PubMed ID: 3112102
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
    Cappelletty DM, Kang SL, Palmer SM, Rybak MJ.
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
    [Abstract] [Full Text] [Related]

  • 13. Serum bactericidal activity and killing rate for volunteers receiving imipenem, imipenem plus amikacin, and ceftazidime plus amikacin against Pseudomonas aeruginosa.
    Van der Auwera P, Klastersky J, Lagast H, Husson M.
    Antimicrob Agents Chemother; 1986 Jul; 30(1):122-6. PubMed ID: 3092729
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparative pharmacokinetics and pharmacodynamics of amikacin and ceftazidime in tricuspid and aortic vegetations in experimental Pseudomonas endocarditis.
    Bayer AS, Crowell DJ, Yih J, Bradley DW, Norman DC.
    J Infect Dis; 1988 Aug; 158(2):355-9. PubMed ID: 3042875
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa.
    Fantin B, Farinotti R, Thabaut A, Carbon C.
    J Antimicrob Chemother; 1994 Mar; 33(3):563-9. PubMed ID: 8040120
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Bactericidal interactions of a beta-lactam and beta-lactamase inhibitors in experimental Pseudomonas aeruginosa endocarditis caused by a constitutive overproducer of type Id beta-lactamase.
    Bayer AS, Selecky M, Babel K, Hirano L, Yih J, Parr TR.
    Antimicrob Agents Chemother; 1987 Nov; 31(11):1750-5. PubMed ID: 3124738
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.